Edwards Lifesciences Corp
EW
View Detailed Chart
86.190USD
+0.400+0.47%
Close 12/05, 16:00（ET）Quotes delayed by 15 min
50.05BMarket Cap
36.59P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+0.47%
5 Days
-0.55%
1 Month
+3.36%
6 Months
+11.18%
Year to Date
+16.43%
1 Year
+20.49%
View Detailed Chart
TradingKey Stock Score of Edwards Lifesciences Corp
Currency: USD Updated: 2025-12-05Key Insights
The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Edwards Lifesciences Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
34
analysts
Buy
Current Rating
94.214
Target Price
+9.31%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Edwards Lifesciences Corp Highlights
StrengthsRisks
Edwards Lifesciences Corporation is a global structural heart innovation company. The Company is engaged in patient-focused medical innovations for structural heart disease and invests in research and development to transform care for those impacted by structural heart disease. Its products are categorized into groups, including Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart (Surgical). It develops transcatheter heart valve replacement technologies designed for the minimally invasive replacement of aortic heart valves. The Edwards SAPIEN family of valves includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra, and the Edwards SAPIEN 3 Ultra RESILIA systems, are catheter-based approaches for treating severe symptomatic aortic stenosis. Its PASCAL PRECISION and Cardioband transcatheter valve repair systems are commercially available in Europe for mitral and tricuspid valve repair.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 5.44B.
Overvalued
The company’s latest PE is 36.70, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 522.58M shares, decreasing 5.55% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 7.64K shares of this stock.
Edwards Lifesciences Corp News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Edwards Lifesciences Corp Info
Edwards Lifesciences Corporation is a global structural heart innovation company. The Company is engaged in patient-focused medical innovations for structural heart disease and invests in research and development to transform care for those impacted by structural heart disease. Its products are categorized into groups, including Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart (Surgical). It develops transcatheter heart valve replacement technologies designed for the minimally invasive replacement of aortic heart valves. The Edwards SAPIEN family of valves includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra, and the Edwards SAPIEN 3 Ultra RESILIA systems, are catheter-based approaches for treating severe symptomatic aortic stenosis. Its PASCAL PRECISION and Cardioband transcatheter valve repair systems are commercially available in Europe for mitral and tricuspid valve repair.
Ticker SymbolEW
CompanyEdwards Lifesciences Corp
CEOMr. Bernard J. Zovighian
Websitehttps://www.edwards.com
FAQs
What is the current price of Edwards Lifesciences Corp (EW)?
The current price of Edwards Lifesciences Corp (EW) is 86.190.
What is the symbol of Edwards Lifesciences Corp?
The ticker symbol of Edwards Lifesciences Corp is EW.
What is the 52-week high of Edwards Lifesciences Corp?
The 52-week high of Edwards Lifesciences Corp is 87.890.
What is the 52-week low of Edwards Lifesciences Corp?
The 52-week low of Edwards Lifesciences Corp is 65.940.
What is the market capitalization of Edwards Lifesciences Corp?
The market capitalization of Edwards Lifesciences Corp is 50.05B.
What is the net income of Edwards Lifesciences Corp?
The net income of Edwards Lifesciences Corp is 4.17B.
Is Edwards Lifesciences Corp (EW) currently rated as Buy, Hold, or Sell?
According to analysts, Edwards Lifesciences Corp (EW) has an overall rating of Buy, with a price target of 94.214.
What is the Earnings Per Share (EPS TTM) of Edwards Lifesciences Corp (EW)?
The Earnings Per Share (EPS TTM) of Edwards Lifesciences Corp (EW) is 2.348.
Related Instruments
-0.85%
-0.30%
-0.44%
+1.18%
-0.41%
-0.23%
-0.15%
-0.62%
-0.19%
-1.46%
-0.31%
-1.14%
+0.58%
-0.47%
+0.05%
-1.94%
+2.20%
-0.13%
+3.56%
